THIORIDAZINE structure
|
Common Name | THIORIDAZINE | ||
---|---|---|---|---|
CAS Number | 50-52-2 | Molecular Weight | 370.574 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 515.7±50.0 °C at 760 mmHg | |
Molecular Formula | C21H26N2S2 | Melting Point | 72-74° | |
MSDS | N/A | Flash Point | 265.7±30.1 °C | |
Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger |
Use of THIORIDAZINEThioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs)[1][2][3][4]. |
Name | thioridazine |
---|---|
Synonym | More Synonyms |
Description | Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs)[1][2][3][4]. |
---|---|
Related Catalog | |
In Vitro | Thioridazine (0.01-100 μM; 48 h) reduces the cell viability of NCI-N87 and AGS cells in a concentration-dependent manner[2]. Thioridazine (15 μM; 24 h) reduces cell viability of the cervical (HeLa, Caski and C33A) and endometrial (HEC-1-A and KLE) cancer cells[4]. Thioridazine (1-15 μM; 24-48 h) induces gastric cancer cell death via the mitochondrial apoptosis pathway and mitochondrial pathway[2]. Thioridazine (15 μM; 24 h) modulates the regulation of cell cycle progression by interfering with the PI3K/Akt pathway and induces G1 cell cycle arrest in cervical and endometrial cancer cells [4]. Thioridazine inhibits the growth of antibiotic-sensitive and multidrug-resistant strains of A. baumannii[3]. Cell Viability Assay[1] Cell Line: NCI-N87 and AGS cells. Concentration: 0.01, 0.1, 0.5, 1, 5, 10, 20, 50, 100 μM. Incubation Time: 48 hours. Result: Exhibited cytotoxicity in gastric cancer cells. Western Blot Analysis[1] Cell Line: NCI-N87 and AGS cells Concentration: 1, 5, 10, 15 μM. Incubation Time: 24, 48 hours. Result: Downregulated the precursors of caspase-9, caspase-8 and caspase-3. |
In Vivo | Thioridazine (25 mg/kg; i.p. every 3 days for 3 weeks) extends the survival of tumor-bearing mice and reduces the number of pluripotent embryonal carcinoma (EC) cells within tumors[5]. Thioridazine (1.0-5.0 mg/kg; s.c.) reduces oral behavior and selectively blocks repetitive head bobbing[1]. Animal Model: Nude and Rag2KO mice were injected with iPS cells or NT2D1 cells[5] Dosage: 25 mg/kg. Administration: I.p. every 3 days for 3 weeks. Result: Reduced the number of OCT4-expressing cells within malignant teratocarcinomas and extended the survival of tumor-bearing mice. With no effect on fertility. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 515.7±50.0 °C at 760 mmHg |
Melting Point | 72-74° |
Molecular Formula | C21H26N2S2 |
Molecular Weight | 370.574 |
Flash Point | 265.7±30.1 °C |
Exact Mass | 370.153748 |
PSA | 57.08000 |
LogP | 6.13 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.677 |
Storage condition | ?20°C |
Water Solubility | Practically insoluble in water, very soluble in methylene chloride, freely soluble in methanol, soluble in ethanol (96 per cent). |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Symbol |
GHS02, GHS06, GHS08 |
---|---|
Signal Word | Danger |
Hazard Statements | H225-H301 + H311 + H331-H370-H412 |
Precautionary Statements | P210-P260-P273-P280-P301 + P310-P311 |
Hazard Codes | F,T |
Risk Phrases | 11-23/24/25-39/23/24/25-52/53 |
Safety Phrases | 16-36/37-45-61 |
RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
~% THIORIDAZINE CAS#:50-52-2 |
Literature: Bourquin et al. Helvetica Chimica Acta, 1958 , vol. 41, p. 1072,1080 |
Precursor 6 | |
---|---|
DownStream 3 | |
[Simultaneous determination of 10 unapproved sedative drugs in feeds by ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry].
Se Pu 30(5) , 457-62, (2012) A new analytical method using ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was developed for screening and confirmation of 10 unapproved sedative... |
|
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
Eukaryotic Cell 12(2) , 278-87, (2013) New, more accessible therapies for cryptococcosis represent an unmet clinical need of global importance. We took a repurposing approach to identify previously developed drugs with fungicidal activity ... |
|
Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.
Expert Rev. Anti. Infect. Ther. 10(8) , 869-73, (2012) Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its ... |
3-Methylmercapto-N-[2'-(N'-methyl-2-piperidyl)ethyl]phenothiazine |
EINECS 200-044-2 |
MFCD00242875 |
Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)- |
10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)- |
2-Methylmercapto-10-[2-(N-methyl-2-piperidyl)ethyl]phenothiazine |
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine |
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine |
THIORIDAZINE |
10-[2-(1-Methyl-2-piperidinyl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine |
10-[2-(1-Methyl-2-piperidinyl)ethyl]-2-(methylthio)-10H-phenothiazine |
10-[2-(1-Methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine |
UNII:N3D6TG58NI |
10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)- |